Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics;Rehospitalisierungsfreie intervalle bei schizophrenen patienten unter oralen atypika versus herkömmlichen depotneuroleptika

Psychiatrische Praxis

Volumn 34, Issue 6, 2007, Pages 289-291

  Gutwinski, Stefan ^a,c   Müller, Peter ^a   Koller, Manfred ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Niedersachsisches Landeskrankenhaus   (Germany)

^c NONE

Author keywords

Antipsychotics; Cost effectiveness; Depot form; Oral form; Rehospitalisation

Indexed keywords

CLOZAPINE; FLUPENTIXOL; NEUROLEPTIC AGENT;

ARTICLE; DRUG DOSAGE FORM COMPARISON; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DELAYED-ACTION PREPARATIONS; FEMALE; FLUPENTHIXOL; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34548673991     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951858     Document Type: Article

References (13)

1. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (Hrsg) Gaebel W, Falkai P (Red). Behandlungsleitlinien Schizophrenie (S3 Praxisleitlinien in Psychiatrie und Psychotherapie). Darmstadt: Steinkopff, 2006
2. Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-191
3. Lieberman JA, Stroup TS et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
4. Leucht S, Barnes TR et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
6. Geddes J, Freemantle N et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376
7. Müller P, Nerenz H, Schaefer E. Rehospitalisierungsrisiko unter atypischen Neuroleptika und typischen Depotneuroleptika - ein Beitrag zur Differenzialindikation. Psychiat Prax 2002; 29: 388-391
8. Conley RR, Kelly DL et al. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003; 15: 23-31
9. Prentice RL. Linear rank test with right censored data. Biometrika 1978; 65: 167-179
10. Kaplan EL, Meyer P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481
11. Conley RR, Tamminga CA et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999; 46: 73-77
12. Meltzer HY, Alphs L et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
13. Müller P, Schöneich D. Einfluss kombinierter Pharmako- und Psychotherapie in einer Schizophrenie-Ambulanz auf Rehospitalisierungszeiten und Behandlungskosten. Psychiat Prax 1992; 19: 91-95